Engineering high‐affinity dual targeting cellular nanovesicles for optimised cancer immunotherapy
Abstract Dual targeting to immune checkpoints has achieved a better therapeutic efficacy than single targeting due to synergistic extrication of tumour immunity. However, most dual targeting strategies are usually antibody dependent which facing drawbacks of antibodies, such as poor solid tumour pen...
Main Authors: | Luyao Zhang, Xu Zhao, Yanan Niu, Xiaoya Ma, Wei Yuan, Jie Ma |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-11-01
|
Series: | Journal of Extracellular Vesicles |
Subjects: | |
Online Access: | https://doi.org/10.1002/jev2.12379 |
Similar Items
-
Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy
by: Shengzhe Jin, et al.
Published: (2024-03-01) -
PD-1 Cellular Nanovesicles Carrying Gemcitabine to Inhibit the Proliferation of Triple Negative Breast Cancer Cell
by: Hualian Zha, et al.
Published: (2022-06-01) -
Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy
by: Shumin Xu, et al.
Published: (2023-05-01) -
Durable Near-Complete Response to Anti-PD-1 Checkpoint Immunotherapy in a Refractory Malignant Solitary Fibrous Tumor of the Pleura
by: James T. Boothe, et al.
Published: (2017-11-01) -
Perioperative immunotherapy for esophageal squamous cell carcinoma
by: Dan D. Wei, et al.
Published: (2024-02-01)